NUREXONE BIOLOGIC INC. (J90) - Total Liabilities
Based on the latest financial reports, NUREXONE BIOLOGIC INC. (J90) has total liabilities worth €1.32 Million EUR (≈ $1.55 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore NUREXONE BIOLOGIC INC. (J90) cash conversion ratio to assess how effectively this company generates cash.
NUREXONE BIOLOGIC INC. - Total Liabilities Trend (2021–2025)
This chart illustrates how NUREXONE BIOLOGIC INC.'s total liabilities have evolved over time, based on quarterly financial data. See J90 book value for net asset value and shareholders' equity analysis.
NUREXONE BIOLOGIC INC. Competitors by Total Liabilities
The table below lists competitors of NUREXONE BIOLOGIC INC. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
BIONXT SOLUTIONS INC.
F:BXT
|
Germany | €9.54 Million |
|
Atossa Genetics Inc
NASDAQ:ATOS
|
USA | $8.22 Million |
|
Excelsior Biopharma
TWO:6496
|
Taiwan | NT$679.78 Million |
|
Seresco S.A.
MC:SCO
|
Spain | €25.40 Million |
|
Manomay Tex India Limited
NSE:MANOMAY
|
India | Rs4.91 Billion |
|
Franklin Wireless Corp
NASDAQ:FKWL
|
USA | $14.76 Million |
|
FASOO.COM Co Ltd
KQ:150900
|
Korea | ₩10.74 Billion |
|
E&E Recycling
TWO:8440
|
Taiwan | NT$165.55 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down NUREXONE BIOLOGIC INC.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is NUREXONE BIOLOGIC INC. worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.63 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.48 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.32 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how NUREXONE BIOLOGIC INC.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for NUREXONE BIOLOGIC INC. (2021–2025)
The table below shows the annual total liabilities of NUREXONE BIOLOGIC INC. from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €1.32 Million ≈ $1.55 Million |
+94.85% |
| 2024-12-31 | €680.00K ≈ $794.99K |
-65.67% |
| 2023-12-31 | €1.98 Million ≈ $2.32 Million |
+183.81% |
| 2022-12-31 | €698.00K ≈ $816.04K |
-57.93% |
| 2021-12-31 | €1.66 Million ≈ $1.94 Million |
-- |
About NUREXONE BIOLOGIC INC.
NurExone Biologic Inc., a pharmaceutical technology company, develops a platform for biologically guided exosome-based therapies for the treatment of central nervous system injuries. It develops and commercializes the ExoTherapy platform for production of exosome-loaded nanodrugs. The company is also developing an off-the-shelf, non-invasive, and novel treatment for the reversal or reduction of p… Read more